CMS and FDA have initiated the ACCESS Model and TEMPO pilot to expand technology-driven care for Medicare chronic condition patients, focusing on outcomes-based payments and regulatory flexibility.

CMS Innovation Center and FDA introduce ACCESS and TEMPO models to integrate digital health devices into Medicare, boosting care and payment innovation for chronic conditions.

FDA and CMS launch pilots to expand Medicare access to digital health technologies through outcome-aligned payments and regulatory flexibility, targeting chronic disease management.

CMS and FDA introduce ACCESS and TEMPO models to enable digital health device integration in traditional Medicare, focusing on outcome-aligned payments, regulatory easing, and expanded patient access.

An overview of key issues in U.S. health insurance, FDA regulatory inconsistencies, health care costs, anti-vaccine impacts, and emerging digital health policies affecting public health.

The Safe Food Coalition urges urgent regulatory action after a Clostridium botulinum outbreak linked to ByHeart infant formula reveals inspection gaps, stressing need for enhanced safety protocols in infant nutrition products.

Explore Medicare coverage guidelines for Botox focusing on FDA-approved medical uses, prior authorization, medical necessity, and cost factors under Medicare Part B and Advantage plans.

Comprehensive 2026 U.S. legislative and regulatory forecast impacting insurance, healthcare, infrastructure, and technology sectors. Key updates on ACA subsidies, FDA reauthorization, transportation, and trade policies shaping compliance and market strategies.

CMS introduces the ACCESS Model to improve Medicare chronic care with digital health innovation and outcome-based payments starting 2026.

Discover the insurance challenges surrounding FDA-approved vertebral body tethering for scoliosis. Understand insurer denial reasons, clinical outcomes, and impact on patient care.